RT Journal Article
T1 Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)
A1 Blanco-Fernandez, Gerardo
A1 Fondevila-Campo, Constantino
A1 Sanjuanbenito, Alfonso
A1 Fabregat-Prous, Joan
A1 Secanella-Medayo, Luis
A1 Rotellar-Sastre, Fernando
A1 Pardo-Sanchez, Fernando
A1 Prieto-Calvo, Mikel
A1 Marin-Ortega, Hector
A1 Sanchez-Cabus, Santiago
A1 Diez-Valladares, Luis
A1 Alonso-Casado, Oscar
A1 Gonzalez-Serrano, Carmen
A1 Carlos Rodriguez-Sanjuan, Juan
A1 Garcia-Plaza, Gabriel
A1 Jaen-Torrejimeno, Isabel
A1 Angel Suarez-Munoz, Miguel
A1 Becerra-Massare, Antonio
A1 Senra-del Rio, Paula
A1 Pando, Elizabeth
A1 Lopez-Andujar, Rafael
A1 Munoz-Forner, Elena
A1 Rodriguez-Lopez, Mario
A1 Pereira, Fernando
A1 Serrablo-Requejo, Alejandro
A1 Sanchez Turrion, Victor
A1 Jimenez Garrido, Manuel
A1 Burdio, Fernando
A1 Martin-Perez, Elena
A1 Estevan-Estevan, Rafael
A1 Lopez-Guerra, Diego
A1 Castell-Gomez, Jose
A1 Salinas-Gomez, Javier
A1 Angel Lopez-Baena, Jose
A1 Lopez-Ben, Santiago
A1 Solar-Garcia, Lorena
A1 Perez-Alonso, Alejandro J.
A1 Alberto Martinez-Insfran, Luis
A1 Luis Blas, Juan
A1 Cornejo, Marian
A1 Gutierrez-Calvo, Alberto
A1 Domingo-del Pozo, Carlos
A1 Ochando-Cerdan, Federico
A1 Munoz-Bellvis, Luis
A1 Rebollar-Saenz, Jose
A1 Sanchez, Belinda
A1 Maria Jover, Jose
A1 Angel Gomez-Bravo, Miguel
A1 Ramia, Jose M.
A1 Rojas-Holguin, Adela
K1 Renal cell carcinoma
K1 Pancreatectomy
K1 Metastases
K1 Recurrence
K1 International study-group
K1 Resection
K1 Surgery
K1 Tumors
K1 Definition
K1 Experience
K1 Survival
K1 Cohort
AB Background: Renal Cell Carcinoma (RCC) occasionally spreads to the pancreas. The purpose of our study is to evaluate the short and long-term results of a multicenter series in order to determine the effect of surgical treatment on the prognosis of these patients.Methods: Multicenter retrospective study of patients undergoing surgery for RCC pancreatic metastases, from January 2010 to May 2020. Variables related to the primary tumor, demographics, clinical characteristics of metastasis, location in the pancreas, type of pancreatic resection performed and data on short and long-term evolution after pancreatic resection were collected.Results: The study included 116 patients. The mean time between nephrectomy and pancreatic metastases' resection was 87.35 months (ICR: 1.51-332.55). Distal pancreatectomy was the most performed technique employed (50 %). Postoperative morbidity was observed in 60.9 % of cases (Clavien-Dindo greater than IIIa in 14 %). The median follow-up time was 43 months (13-78). Overall survival (OS) rates at 1, 3, and 5 years were 96 %, 88 %, and 83 %, respectively. The disease-free survival (DFS) rate at 1, 3, and 5 years was 73 %, 49 %, and 35 %, respectively. Significant prognostic factors of relapse were a disease free interval of less than 10 years (2.05 [1.13-3.72], p 0.02) and a history of previous extrapancreatic metastasis (2.44 [1.22-4.86], p 0.01).Conclusions: Pancreatic resection if metastatic RCC is found in the pancreas is warranted to achieve higher overall survival and disease-free survival, even if extrapancreatic metastases were previously removed. The existence of intrapancreatic multifocal compromise does not always warrant the performance of a total pancreatectomy in order to improve survival. (C) 2021 The Authors. Published by Elsevier Ltd.
PB Elsevier sci ltd
SN 0748-7983
YR 2022
FD 2022-01-31
LK https://hdl.handle.net/10668/26474
UL https://hdl.handle.net/10668/26474
LA en
DS RISalud
RD Apr 10, 2025